Neridronic acid for treating bone marrow lesion
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as bone marrow lesion.
1. A method of treating a bone marrow lesion comprising: selecting a patient having 1) a bone marrow lesion and 2) OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, and administering neridronic acid to the patient for the treatment of the bone marrow lesion.
2. The method of claim 1 , wherein the neridronic acid is administered daily.
3. The method of claim 1 , wherein the neridronic acid is administered weekly.
4. The method of claim 1 , wherein the neridronic acid is administered monthly.
5. The method of claim 1 , wherein the patient is suffering from complex regional pain syndrome.
6. The method of claim 1 , wherein the neridronic acid is administered orally.
7. The method of claim 1 , wherein the neridronic acid is administered parenterally.
8. The method of claim 1 , wherein the neridronic acid is administered in at least two doses.
9. The method of claim 8 , wherein the neridronic acid is administered within a period of six months.
10. The method of claim 1 , wherein a total of about 100 mg to 500 mg of the neridronic acid is administered.
11. The method of claim 1 , wherein each dose contains about 50 mg to about 60 mg of the neridronic acid.
12. The method of claim 1 , wherein the neridronic acid is administered intravenously.
13. The method of claim 12 , wherein the each dose contains about 100 mg of the neridronic acid.
14. The method of claim 13 , wherein the neridronic acid is administered in at least four about equal doses.
15. The method of claim 14 , wherein the second dose of the neridronic acid is administered 3 days after the first dose of the neridronic acid is administered.
16. The method of claim 1 , wherein the patient has suffered from the bone marrow lesion for at least 1 month.
17. The method of claim 1 , wherein the patient is at least 18 years of age.
18. The method of claim 1 , wherein the neridronic acid is administered in a single dose or in divided doses.
19. The method of claim 6 , wherein the neridronic acid is orally administered weekly.
20. The method of claim 6 , wherein the neridronic acid is orally administered two or three times a month.
21. The method of claim 6 , wherein 40 mg to 60 mg of the neridronic acid is orally administered to the patient per week.
22. The method of claim 6 , wherein about 40 mg to about 60 mg per week of the neridronic acid is orally administered to the patient for six consecutive weeks.
23. The method of claim 6 , wherein a monthly total of about 200 mg/m 2 to about 300 mg/m 2 of the neridronic acid is administered to the patient in two or three doses administered within a month.
24. The method of claim 1 , wherein the neridronic acid is administered in a dosage form containing a salt form of the neridronic acid.
25. The method of claim 1 , wherein the neridronic acid is administered in a dosage form containing a disodium salt form of the neridronic acid.
26. The method of claim 25 , wherein an equivalent of about 50 mg to about 150 mg of the neridronic acid per week is orally administered.
27. The method of claim 26 , wherein the neridronic acid is administered to the patient for about four to about six consecutive weeks.
28. The method of claim 1 , wherein the patient is suffering from osteoarthritis of the knee with bone marrow lesions.
29. The method of claim 1 , wherein administering the neridronic acid results in a reduction in size of bone marrow lesions of at least about 20% relative to baseline.
30. The method of claim 1 , the neridronic acid is co-administered with a steroid in a dosage form.